Defining Predictors of RT Response to Vedolizumab in IBD
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The overall goal of the study is to develop data that can convincingly guide clinicians on
the use and efficacy of vedolizumab in patients with small bowel CD. There is an unmet need
to identify response to vedolizumab in small bowel CD using objective endpoints. Current data
suggest that MR enterography may meet this unmet need. There is an additional unmet need to
develop predictive models incorporating both clinical and baseline radiological and
endoscopic variables with higher discriminatory performance in identifying longer term
clinical remission with vedolizumab. Finally, this proposal is strengthened by the
exploratory studies which may identify new proteomic biomarkers that correlate with longer
term radiological response with vedolizumab reflecting its latency of response. If
successful, these serum biomarkers may guide a personalized approach to the treatment of
small bowel CD with vedolizumab, allowing early identification of PNR, monitoring disease
activity and the pharmacodynamics of vedolizumab.